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(N  2379). Treatment completion is defined as receiving
at least 180 days of therapy at a minimum therapeutic
dose defined by the AHCPR guidelines. Patients were in-
cluded if they had a new ICD-9 diagnosis code for depres-
sion and were newly initiated on antidepressant therapy.
Patients were excluded if they were less than 18 years old,
had a diagnosis indicating schizophrenia or bipolar de-
pression, did not have at least 9 months of follow-up data
available, or were ineligible for coverage by the plan.
RESULTS: Total drug costs were higher in patients who
completed therapy ($704 versus $311; P  0.001); how-
ever overall healthcare costs were similar ($2672 versus
$2623, P  0.84). After controlling for confounding fac-
tors, there was a significant relationship between overall
cost and the specific antidepressant selected. Total costs
were similar for patients who switched or augmented
with a second antidepressant.
CONCLUSION: Patients with a diagnosis of depression
who complete therapy have similar overall healthcare
costs compared to those who do not. The initial antide-
pressant selected significantly contributes to overall costs.
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Antidepressants are a rapidly growing class of drugs used
to treat depression. The newer agents have been demon-
strated to improve patient outcomes and lower overall
health cost. Despite these benefits, the cost of the newer
antidepressants may be significant and may be influenced
by patterns of use. This study was undertaken to examine
three potential cost drivers associated with antidepres-
sants: persistence rate; switch rate; and concurrent use of
adjunctive antianxiety/sedative/hypnotic therapy.
OBJECTIVES: Examine the rates of persistence, switch-
ing, and concurrent use of adjunctive antianxiety/seda-
tive/hypnotic agents associated with the newer antide-
pressants and determine if there is a difference between
agents. Our objective was to determine if these differ-
ences in pattern of use add “cost” to treatment. Antide-
pressants studied included fluoxetine, paroxetine, sertra-
line, and venlafaxine.
METHODS: We performed a retrospective analysis of
medical and pharmaceutical claims data for 2,000,000
commercial HMO members for a 2-year period beginning
July 1996. Inclusion criteria for the study were: 1) diagno-
sis of depression; and 2) no antidepressant use or medical
activity related to depression for 3 months prior to admis-
sion to the study. The data were stratified into two groups
for review: non-capitated and capitated plans. Statistical
analysis was performed comparing each group.
RESULTS: There is a statistically significant difference
between some agents in the rates of switching and the use
of adjunctive medications. As switching increased, total
medical cost increased. Medical cost increased to $120
from $104 per depressed member per month at switching
rates of 29.5% and 15.3%, respectively. The variation in
the use and cost of adjunctive medications was also sta-
tistically significant between some agents. The cost ranged
from $23.71 to $2.74 for adjunctive medications per de-
pressed member per month.
CONCLUSION: When determining which antidepres-
sant drug to use, it is prudent to consider additional costs
associated with switching and adjunctive medication.
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Depression is a common, disabling and expensive psychi-
atric disorder. Management of depression has become a
heavy financial burden on both patients and society.
Pharmacotherapy can reduce the cost, but the question is
which drugs are most cost-beneficial.
OBJECTIVE: The purpose of this study is to investigate
and compare the costs and benefits of different antide-
pressants in the first year management of major depres-
sive disorder, from the perspective of a managed care
third-party payer.
METHODS: A decision tree was used to model the clini-
cal management of major depressive disorder (MDD).
Imipramine and paroxetine were chosen as examples of
two main classes of antidepressants, namely, the tricyclic
antidepressants (TCAs) and selective serotonin reuptake
inhibitors (SSRIs). A cost-benefit analysis was conducted.
The cost is the cost of the antidepressant drug treatment.
The benefit is defined as the average cost of avoided
dropout. The net benefit is the difference between the de-
fined benefit and the cost of each drug treatment.
RESULTS: Within the first year time period, the cost
of using imipramine was $81.39 and the benefit was
$169.25. For paroxetine, the cost was $261.33 and the
benefit was $201.81. The net benefit of imipramine was
$87.86 and for paroxetine, $59.52.
CONCLUSION: Based on the assumptions and parame-
ters included in this model, imipramine was found to be a
preferred choice of antidepressant in the management of
MDD during the first year compared with paroxetine.
Sensitivity analysis shows that the results are robust to
the average whole sale prices of imipramine and paroxet-
ine as well as the type of depression (“dysthymic-neu-
rotic” or “reactive”).
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